Written by The UK Host Cell Protein Testing Market is gaining importance as the UK’s biopharmaceutical industry expands and manufacturers place greater emphasis on product quality and safety. The market was valued at USD 96.6 million in 2024 and is projected to reach USD 147.4 million by 2035, registering a CAGR of 3.92% during 2025–2035. Increasing regulatory requirements and demand for biologics are supporting the growth of host cell protein testing solutions.
Host cell protein testing is an important part of biopharmaceutical development because residual proteins from production host cells need to be carefully monitored. UK manufacturers are increasingly adopting reliable analytical methods to support product characterization, quality assurance, and regulatory compliance. This growing focus is encouraging investment in testing technologies that can deliver accurate and consistent results.
PCR-based assays currently represent the largest testing segment, supported by their sensitivity and specificity, while ELISA-based assays are identified as the fastest-growing segment due to their user-friendly nature and cost-effectiveness. Biopharmaceutical companies account for the largest end-user segment, while contract research organizations are experiencing strong growth as more companies outsource specialized testing activities.
Looking ahead, automation, high-throughput screening, artificial intelligence, and advanced analytical techniques are expected to create new opportunities. Testing providers that offer faster workflows, improved sensitivity, and integrated analytical services can benefit from rising demand. With continued growth in biologics and increasing regulatory scrutiny, the UK host cell protein testing industry is expected to maintain steady expansion through 2035.